BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10636463)

  • 1. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin.
    Nakamura K; Kariyazono H; Moriyama Y; Toyohira H; Kubo H; Yotsumoto G; Taira A; Yamada K
    Blood Coagul Fibrinolysis; 1999 Dec; 10(8):513-9. PubMed ID: 10636463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
    Nakamura K; Kariyazono H; Masuda H; Sakata R; Yamada K
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):391-7. PubMed ID: 11505083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
    Pietraszek MH; Takada Y; Taminato A; Yoshimi T; Watanabe I; Takada A
    Thromb Res; 1993 Apr; 70(2):131-8. PubMed ID: 8322284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
    Satoh K; Yatomi Y; Ozaki Y
    J Thromb Haemost; 2006 Feb; 4(2):479-81. PubMed ID: 16420586
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
    Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
    Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 5-hydroxytryptamine2A receptor antagonist sarpogrelate hydrochloride inhibits acute platelet aggregation in injured endothelium.
    Houkin K; Nakayama N; Nonaka T; Koyanagi I
    J Int Med Res; 2006; 34(1):65-72. PubMed ID: 16604825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic analysis of antiplatelet effect of sarpogrelate hydrochloride and its application to drug dosage regimen--modeling based on reversible inhibition of 5-HT2 serotonergic receptor in the platelet membrane by sarpogrelate hydrochloride and its metabolite].
    Shimizu T; Yamada Y; Tashita A; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Yakugaku Zasshi; 1999 Nov; 119(11):850-60. PubMed ID: 10590712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease.
    Rydzewski A; Urano T; Hachiya T; Kaneko H; Baba S; Takada Y; Takada A
    Thromb Res; 1996 Dec; 84(6):445-52. PubMed ID: 8987165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.
    Kariyazono H; Nakamura K; Shinkawa T; Yamaguchi T; Sakata R; Yamada K
    Thromb Res; 2001 Mar; 101(6):445-53. PubMed ID: 11323002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
    Kajiwara I; Soejima H; Miyamoto S; Ogawa H
    Thromb Res; 2011 Dec; 128(6):547-51. PubMed ID: 21722942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits.
    Takano S
    Arch Int Pharmacodyn Ther; 1995; 330(3):297-308. PubMed ID: 8836449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
    Ogawa T; Sugidachi A; Asai F; Koike H
    Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
    Kobayashi S; Satoh M; Namikoshi T; Haruna Y; Fujimoto S; Arakawa S; Komai N; Tomita N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2008 Apr; 12(2):119-125. PubMed ID: 18175064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT
    Kubacka M; Kazek G; Kotańska M; Filipek B; Waszkielewicz AM; Mogilski S
    Eur J Pharmacol; 2018 Jan; 818():263-270. PubMed ID: 29111111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
    Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
    Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
    Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sarpogrelate hydrochloride, a 5-hydroxytryptamine2 receptor antagonist, on allograft arteriosclerosis after aortic transplantation in rats.
    Watada S; Harada H; Matsubara K; Obara H; Matsumoto K; Ando N; Kitagawa Y
    Transpl Immunol; 2013 Dec; 29(1-4):162-6. PubMed ID: 23851153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
    Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
    Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocyte-protective effect of sarpogrelate hydrochloride (Anplag ®), a selective 5-HT2 receptor antagonist: an in vitro study.
    Nakamura K; Kawahito K
    J Artif Organs; 2010 Sep; 13(3):178-81. PubMed ID: 20799047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression.
    Rand ML; Perry DW; Packham MA; Gemmell CH; Yeo EL; Kinlough-Rathbone RL
    Am J Hematol; 1996 Aug; 52(4):288-94. PubMed ID: 8701947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.